Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel

Cui Meng,1–3* Weipeng Wei,1,2* Yuhe Wang,1,3 Kunqin Zhang,1,2 Ting Zhang,1,2 Yunyan Tang,1,2 Fushan Tang1,2 1Department of Clinical Pharmacy, School of Pharmacy, Zunyi Medical University, Zunyi 563006, People’s Republic of China; 2The Key Laboratory of Clinical Pharmacy in Zunyi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meng C, Wei W, Wang Y, Zhang K, Zhang T, Tang Y, Tang F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	RADA16-I hydrophobic drug delivery system antitumor Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ec001ff920524403b258cc9ad0933b67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec001ff920524403b258cc9ad0933b67
record_format	dspace
spelling	oai:doaj.org-article:ec001ff920524403b258cc9ad0933b672021-12-02T09:56:51ZStudy of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel1178-2013https://doaj.org/article/ec001ff920524403b258cc9ad0933b672019-09-01T00:00:00Zhttps://www.dovepress.com/study-of-the-interaction-between-self-assembling-peptide-and-mangiferi-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Cui Meng,1–3* Weipeng Wei,1,2* Yuhe Wang,1,3 Kunqin Zhang,1,2 Ting Zhang,1,2 Yunyan Tang,1,2 Fushan Tang1,2 1Department of Clinical Pharmacy, School of Pharmacy, Zunyi Medical University, Zunyi 563006, People’s Republic of China; 2The Key Laboratory of Clinical Pharmacy in Zunyi City, Zunyi 563006, People’s Republic of China; 3Department of Pharmacy, The First Hospital Affiliated to Zunyi Medical University, Zunyi 563003, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fushan TangSchool of Pharmacy, Zunyi Medical University, Zunyi 563006, People’s Republic of ChinaTel +8685128642337Email fstang@vip.163.comObjective: This study aimed to investigate the interaction between the ion-complementary self-assembling peptide RADA16-I and the hydrophobic drug mangiferin (MA), and the potential of the self-assembling peptide to be exploited as a drug carrier of MA.Methods: The RADA16-I–MA suspension was prepared by magnetic stirring, followed by fluorescence spectrophotometry, particle size determination, rheological properties analysis, and in vitro release assay to characterize the interaction between RADA16-I and MA. Then, the effects of in situ MA-loaded hydrogel on the proliferation of KYSE 30 and DLD-1 tumor cells and the toxic effect of the hydrogel on 293T renal epithelial cells were studied by the Cell Counting Kit 8 method.Results: The RADA16-I–MA suspension was formed in water under magnetic stirring; the in situ hydrogel was formed when the suspension was added to PBS. The particle size in the RADA16-I–MA suspension was around 300–600 nm with an average size of 492 nm. Within 24 h, the cumulative release of MA from the RADA16-I–MA hydrogel was about 80%. The release rate of MA from the hydrogel was dependent on the concentration of RADA16-I and the release can be fitted with a first-order kinetic equation. The results suggested that the self-assembling peptide can stabilize MA in water to form a relatively stable suspension; the results also indicated that controlled release of MA from the RADA16-I–MA in situ hydrogel formed from the RADA16-I–MA suspension can be achieved by adjusting the concentration of the peptide in suspension. The cell viability studies showed that the RADA16-I–MA in situ hydrogel not only can maintain or enhance the intrinsic proliferation inhibition effects of MA on tumor cells, but also can reduce the toxicity of MA to normal cells.Conclusion: The self-assembling peptide RADA16-I can be a potential candidate for constructing a delivery system of the hydrophobic drug MA.Keywords: RADA16-I, hydrophobic drug, delivery system, antitumorMeng CWei WWang YZhang KZhang TTang YTang FDove Medical PressarticleRADA16-Ihydrophobic drugdelivery systemantitumorMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 7447-7460 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	RADA16-I hydrophobic drug delivery system antitumor Medicine (General) R5-920
spellingShingle	RADA16-I hydrophobic drug delivery system antitumor Medicine (General) R5-920 Meng C Wei W Wang Y Zhang K Zhang T Tang Y Tang F Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
description	Cui Meng,1–3* Weipeng Wei,1,2* Yuhe Wang,1,3 Kunqin Zhang,1,2 Ting Zhang,1,2 Yunyan Tang,1,2 Fushan Tang1,2 1Department of Clinical Pharmacy, School of Pharmacy, Zunyi Medical University, Zunyi 563006, People’s Republic of China; 2The Key Laboratory of Clinical Pharmacy in Zunyi City, Zunyi 563006, People’s Republic of China; 3Department of Pharmacy, The First Hospital Affiliated to Zunyi Medical University, Zunyi 563003, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fushan TangSchool of Pharmacy, Zunyi Medical University, Zunyi 563006, People’s Republic of ChinaTel +8685128642337Email fstang@vip.163.comObjective: This study aimed to investigate the interaction between the ion-complementary self-assembling peptide RADA16-I and the hydrophobic drug mangiferin (MA), and the potential of the self-assembling peptide to be exploited as a drug carrier of MA.Methods: The RADA16-I–MA suspension was prepared by magnetic stirring, followed by fluorescence spectrophotometry, particle size determination, rheological properties analysis, and in vitro release assay to characterize the interaction between RADA16-I and MA. Then, the effects of in situ MA-loaded hydrogel on the proliferation of KYSE 30 and DLD-1 tumor cells and the toxic effect of the hydrogel on 293T renal epithelial cells were studied by the Cell Counting Kit 8 method.Results: The RADA16-I–MA suspension was formed in water under magnetic stirring; the in situ hydrogel was formed when the suspension was added to PBS. The particle size in the RADA16-I–MA suspension was around 300–600 nm with an average size of 492 nm. Within 24 h, the cumulative release of MA from the RADA16-I–MA hydrogel was about 80%. The release rate of MA from the hydrogel was dependent on the concentration of RADA16-I and the release can be fitted with a first-order kinetic equation. The results suggested that the self-assembling peptide can stabilize MA in water to form a relatively stable suspension; the results also indicated that controlled release of MA from the RADA16-I–MA in situ hydrogel formed from the RADA16-I–MA suspension can be achieved by adjusting the concentration of the peptide in suspension. The cell viability studies showed that the RADA16-I–MA in situ hydrogel not only can maintain or enhance the intrinsic proliferation inhibition effects of MA on tumor cells, but also can reduce the toxicity of MA to normal cells.Conclusion: The self-assembling peptide RADA16-I can be a potential candidate for constructing a delivery system of the hydrophobic drug MA.Keywords: RADA16-I, hydrophobic drug, delivery system, antitumor
format	article
author	Meng C Wei W Wang Y Zhang K Zhang T Tang Y Tang F
author_facet	Meng C Wei W Wang Y Zhang K Zhang T Tang Y Tang F
author_sort	Meng C
title	Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
title_short	Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
title_full	Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
title_fullStr	Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
title_full_unstemmed	Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
title_sort	study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/ec001ff920524403b258cc9ad0933b67
work_keys_str_mv	AT mengc studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel AT weiw studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel AT wangy studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel AT zhangk studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel AT zhangt studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel AT tangy studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel AT tangf studyoftheinteractionbetweenselfassemblingpeptideandmangiferinandinvitroreleaseofmangiferinfrominsituhydrogel
_version_	1718397918122082304

Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel

Ejemplares similares